Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

BACKGROUND: The monoclonal antibody daratumumab, approved for treating myeloma, targets CD38, a protein on myeloma and also on CD34+ hematopoietic progenitor cells. Because mobilized CD34+ cells are critical for stem cell transplant, we investigated the in vitro activity of daratumumab on mobilized...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xun, Wong, Sandy W., Zhou, Ping, Chaulagain, Chakra P., Doshi, Parul, Klein, Andreas K., Sprague, Kellie, Kugelmass, Adin, Toskic, Denis, Warner, Melissa, Miller, Kenneth B., Lee, Lisa, Varga, Cindy, Comenzo, Raymond L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192105/
https://www.ncbi.nlm.nih.gov/pubmed/30356940
http://dx.doi.org/10.1186/s40164-018-0119-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192105/
https://www.ncbi.nlm.nih.gov/pubmed/30356940
http://dx.doi.org/10.1186/s40164-018-0119-4

Ejemplares similares